The discontinuation of the PDS0101 Phase 3 trial is a significant negative catalyst, effectively writing off the company's most advanced asset. The entire valuation now rests on PDS0301 Phase 2b data expected over the next 18-24 months, creating a binary, high-risk profile. Traders should monitor for any partnership announcements for PDS0101 and the upcoming Q2 earnings on August 13 for cash runway details.
Drugs in focus
PDSB drug pipeline →PDS0301
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
- Next catalyst
- None dated
What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 11 $0.2570entry
- T+1 · 3mo ago −5.84%α −6.09% · $0.2420
- T+5 · 3mo ago −19.07%α −18.66% · $0.2080
- T+20 · 2mo ago +14.01%α +15.07% · $0.2930
- T+60 · 13d ago +394.16%α +394.30% · $1.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer (mCRC) and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, seeking a partnership for PDS0101 instead. The company cited encouraging Phase 2 data for PDS0301, including a 71% ORR at 6 months and 80% 24-month survival in MSS/pMMR mCRC with liver metastases. This is a material pipeline restructuring that abandons the most advanced program (PDS0101 Phase 3) in favor of an earlier-stage asset, creating significant binary risk around PDS0301's upcoming Phase 2b data.
Key Facts
- PDS Biotech is discontinuing the PDS0101 Phase 3 VERSATILE-003 trial and ceasing further internal investment in PDS0101.
- The company is prioritizing PDS0301, an earlier-stage tumor-targeted immunocytokine, as its lead development program.
- PDS0301 Phase 2 data in MSS/pMMR mCRC with liver metastases showed a 71% ORR at 6 months and an 80% 24-month survival rate.
- PDS0301 has been evaluated in over 380 patients with an encouraging safety profile.
- A randomized Phase 2b trial for PDS0301 has been designed with FDA feedback, with advancement expected over the next 18-24 months.
- The company will announce Q2 2026 financial results on August 13, 2026.
Financial Impact
No financial figures provided in the filing. The company is a clinical-stage biotech with no approved products or reported revenue. The strategic refocus involves discontinuing the most advanced pipeline program (PDS0101 Phase 3), which represents a significant write-off of prior development investment.
Risk Factors
- PDS0301 Phase 2b trial may fail to replicate earlier efficacy signals, resulting in a complete loss of enterprise value.
- No partnership for PDS0101 may materialize, leaving zero value from that program.
- Cash runway may be insufficient to complete the PDS0301 Phase 2b trial without dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032142 |
| Document: ef20079931_8k.htm | 0001140361-26-032142 |
| Document: 0001140361-26-032142-index-headers.html | 0001140361-26-032142 |
| Document: 0001140361-26-032142-index.html | 0001140361-26-032142 |
| Document: 0001140361-26-032142.txt | 0001140361-26-032142 |
Track record
28 reports on PDSB
7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers